In meeting the growth ahead for clinical trials there must be a focus on efficiency as their supply already suffers from major issues with wastage levels. This is lack of control is problematic with the rising public scrutiny on spending by pharmaceutical companies.
Forecasting and demand planning
When sites are under supplied, sponsors may be forced to halt enrolment or even freeze patient treatments. This could have a large influence on the outcomes of a trial. Due to a range of factors, study design, patient enrolment, quantity of sites, site location, that can suddenly change the level of supplies needed for a trial to run, supply managers reduce the risk of stock outs by supplying a surplus of medicine. This in many cases spills over to become overage – when the investigational medicines have to be wasted at the end of a trial or hit their expiry dates before consumption.
By 2020, pharma cold chain logistics spend is predicted to exceed $16 billion. Despite this huge investment, Pharmaceutical supply chains still face tremendous challenges. We sat down with keynote speaker Jack Shaw, Executive Director of the American Blockchain Council, Technology Futurist to discuss this and the following:
-Blockchain's direct impact on the Pharma Supply Chain
-Blockchain technology's affect on cold chain logistics
-Cold chain pharmaceuticals' preparation for the future of technology
We sat down with David Merrit, Executive Vice President of Public Affairs and Strategy, America's Health Insurance Plans to discuss Healthcare Reform. He said "The Trump Administration has put a very bright spotlight on rising prescription drug costs... Their focus has been on reducing regulation, increasing competition, and reducing what patients pay." Learn more about our conversation with David and hear what he has to say on:
- Healthcare Reform's affect on the pharma supply chain
- The national healthcare reform law affect on the future of the pharma supply Chain
- His advise on healthcare reform to the presidential campaigns
We sat down with one of our keynote speakers Bill Mahorney, Chief, Enforcement Division, FMCSA, Department of Transportation. As one of the key players responsible for enforcing the ELD Mandate, Bill will be addressing how this new law will affect the supply chain, logging books, hours of service regulations and cross-industry collaboration. To give you a sneak peek as to what you can expect to hear about onsite, we sat down with Bill to discuss what the ELD Mandate is and how it impacts the supply chain.
Though life sciences companies see value across the full supply chain, it’s the last mile that matters the most to the customer. When customers can’t get what they want when they want it due to product loss, theft, spoilage, counterfeiting or other disruptions, it can be incredibly damaging to a company’s brand and bottom line.
With this in mind, we surveyed 150+ pharma logistics leaders to learn more about the key challenges, solutions and trends impacting the last mile of the life sciences supply chain. Highlights include:
- Analysis of what causes the most last mile disruptions and how firms are addressing these issues
- An overview of our respondents top strategic priorities
- Facts & figures that outline where cold chain leaders are looking to invest on 2018 & 2019
Ahead of the 16th Global Forum taking place September 24-28, 2018 in Philadelphia, PA, we sat down with keynote speaker Tom Bonkenburg, Director, European Operations, St. Onge Company to discuss:
- How robotics are impacting the the pharma supply chain sector specifically
- Common barriers to automation adoption and how to overcome them
- What life sciences supply chain leaders need to do today to prepare for a future of increased automation
This whitepapers covers the latest pharmaceutical logistics regulatory developments around the globe related to FMD, MHRA, ICH Q12, PACMP, GMP, DSCSA and more! Designed specifically to keep you up to date with key developments that we believe with shape the compliance agenda over the next year, key developments that you will need to tune in for! Highlights include:
- GMP inspections international collaboration efforts
- Supply Chain Security and Traceability – GPS
- EMA regulations
- Points to remember for your next GDP inspection
- The latest on Human Drug Compounding Outsourcing Facilities regulations
- An analysis of ICH Q12 concepts
- The cost of Brexit and the road forward
- An overview of EU's recently published report detailing the implementation of the Falsified Medicines Directive (FMD)
Plus! Commentary by 2018 Cold Chain Global Forum speakers:
- Rafik Bishara, Ph.D, former Director QKMTS, Eli Lilly and Company
- Ajay Pazhayattil, Former Associate Director, TOPV Apotex Inc.
Pharma is one of the most conservative industries –namely due to the fact that its products are high risk – very influential to the health, well-being and survival of their consumers. Regulations must be met to ensure that medicine quality and patient safety is protected. Therefore any changes, be it to product or process, need to be controlled to ensure that these vital elements are not in anyway jeopardized.
In the latest article by Pharma IQ,we uncover:
- How to identify and overcome common obstacles to change management in pharma
- Establishing standardized packaging vendor qualification requirements
- Why collaboration and intelligence sharing between drug manufacturers could drastically improve the landscape for the general market.
- And more!
Features insights by:
- Guy Hoskens, Clinical Supply Chain Logistics Expert, Janssen, Pharmaceutical
- Tonino Antonetti, Executive Director, Regulatory Affairs, Quality Management, Safety & Health, Roche Diagnostics
- Craig Vermeyen, Senior Manager, Packaging Engineer, Kite Pharma
To receive a copy of this article via email, write us at firstname.lastname@example.org with "16CCGF Content Request: Change & Collaboration in Pharma Logistics" in the subject line.
Experts have asserted that despite recent developments, pharmaceutical supply chains are still far from reaching their full technological potential. However, Blockchain holds significant promise to advance the digital strength of medicine supply. In this whitepaper, we explore:
- What is blockchain and how can it be applied to cold chain?
- Who in life sciences is currently using blockchain and for what?
- How will the emergence of blockchain impact the industry over the next decade?
Plus! We provide an overview of potential use cases for block chain such as:
- Leveraging R&D data for collaborative research
- Dynamic pricing managed for raw materials
- Compliance and quality tracking
- Pharmacovigilance reporting
- Temperature control
- Temperature monitoring and control